A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas.
David Grosshans, MD
Open to Accrual
Date Opened To Accrual
August 02 2017
Lower Grade Glioma
To determine whether proton therapy, compared to IMRT, preserves cognitive outcomes over time as measured by the Clinical Trial Battery Composite (CTB COMP) score (calculated from the Hopkins Verbal Learning Test Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Controlled Oral Word Association (COWA) test, Trail Making Test (TMT) Part A and Part B
Histologically proven diagnosis of supratentorial, WHO grade II or III astrocytoma, oligodendroglioma or oligoastrocytoma, with IDH mutation confirmed by central review prior to step 2 registration.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.